Elicio Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ELTX research report →
About the company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
- CEO
- Robert T. Connelly
- IPO
- 2021
- Employees
- 32
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $61.46M
- P/E
- -1.36
- P/S
- 0.00
- P/B
- -40.81
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -2748.16%
- ROIC
- -227.73%
- Revenue
- $0 · 0.00%
- Net Income
- $-39,571,000 · 23.75%
- EPS
- $-2.58 · 39.29%
- Op Income
- $-37,714,000
- FCF YoY
- 0.50%
- 52W High
- $16.00
- 52W Low
- $2.66
- 50D MA
- $9.47
- 200D MA
- $9.62
- Beta
- 1.44
- Avg Volume
- 1.50M
Get TickerSpark's AI analysis on ELTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 2, 26 | Connelly Robert | other | 147,200 |
| Feb 2, 26 | Connelly Robert | other | 73,600 |
| Feb 2, 26 | Shah Preetam | other | 47,900 |
| Feb 2, 26 | Shah Preetam | other | 24,000 |
| Feb 2, 26 | DeMuth Peter | other | 41,600 |
| Feb 2, 26 | DeMuth Peter | other | 20,800 |
| Feb 2, 26 | Haqq Christopher | other | 25,400 |
| Feb 2, 26 | Haqq Christopher | other | 50,900 |
| Dec 9, 25 | DeMuth Peter | other | 362 |
| Dec 9, 25 | DeMuth Peter | other | 362 |
Our ELTX coverage
Recent articles, reports, and earnings notes.
No research on ELTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ELTX report →Similar companies
Peers in the same neighborhood.